EC Number   |
Disease |
PubMed ID |
Title of Publication  |
Category |
Confidence Level |
|---|
   2.4.1.219 | Diabetes Mellitus |
22098444 |
Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. |
diagnostic usage |
1 |
| 2.4.1.219 | Diabetes Mellitus |
22098444 |
Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. |
therapeutic application |
2 |
| 2.4.1.219 | Diabetes Mellitus |
22098444 |
Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. |
ongoing research |
3 |
| 2.4.1.219 | Diabetes Mellitus |
22098444 |
Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. |
unassigned |
0 |
| 2.4.1.219 | Diabetes Mellitus, Type 2 |
22098444 |
Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. |
diagnostic usage |
1 |
| 2.4.1.219 | Diabetes Mellitus, Type 2 |
22098444 |
Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. |
therapeutic application |
2 |
| 2.4.1.219 | Diabetes Mellitus, Type 2 |
22098444 |
Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. |
ongoing research |
3 |
| 2.4.1.219 | Diabetes Mellitus, Type 2 |
22098444 |
Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. |
unassigned |
0 |
| 2.4.1.219 | Gaucher Disease |
33361282 |
Human glucocerebrosidase mediates formation of xylosyl-cholesterol by ?-xylosidase and transxylosidase reactions. |
causal interaction |
4 |
| 2.4.1.219 | Gaucher Disease |
33361282 |
Human glucocerebrosidase mediates formation of xylosyl-cholesterol by ?-xylosidase and transxylosidase reactions. |
unassigned |
0 |
